{"id":"https://openalex.org/W1502126985","doi":"https://doi.org/10.1111/j.1528-1167.2012.03598.x","title":"Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial\u2010onset seizures: A phase IIb, randomized, controlled trial","display_name":"Efficacy and tolerability of adjunctive brivaracetam in adults with uncontrolled partial\u2010onset seizures: A phase IIb, randomized, controlled trial","alternate_titles":[],"publication_year":2012,"publication_date":"2012-07-19","ids":{"openalex":"https://openalex.org/W1502126985","doi":"https://doi.org/10.1111/j.1528-1167.2012.03598.x","mag":"1502126985","pmid":"https://pubmed.ncbi.nlm.nih.gov/22813235"},"language":"en","primary_location":{"id":"doi:10.1111/j.1528-1167.2012.03598.x","doi":"https://doi.org/10.1111/j.1528-1167.2012.03598.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1528-1167.2012.03598.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1528-1167.2012.03598.x","source":{"id":"https://openalex.org/S203153751","display_name":"Epilepsia","issn_l":"0013-9580","issn":["0013-9580","1528-1157","1528-1167"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W1502126985"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1528-1167.2012.03598.x","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059287667","display_name":"Wim Van Paesschen","orcid":"https://orcid.org/0000-0002-8535-1699","observed_orcids":["https://orcid.org/0000-0002-8535-1699"]},"institutions":[{"id":"https://openalex.org/I2800231306","display_name":"Universitair Ziekenhuis Leuven","ror":"https://ror.org/0424bsv16","country_code":"BE","type":"healthcare","lineage":["https://openalex.org/I2800231306"]}],"countries":["BE"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Wim Van Paesschen","raw_affiliation_strings":["Department of Neurology, University Hospital, Leuven, Belgium. wim.vanpaesschen@uz.kuleuven.ac.be","Department of Neurology, University Hospital Leuven, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Neurology, University Hospital, Leuven, Belgium. wim.vanpaesschen@uz.kuleuven.ac.be","institution_ids":["https://openalex.org/I2800231306"]},{"raw_affiliation_string":"Department of Neurology, University Hospital Leuven, Belgium","institution_ids":["https://openalex.org/I2800231306"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088572719","display_name":"\u00c9douard Hirsch","orcid":"https://orcid.org/0000-0003-0833-8850","observed_orcids":["https://orcid.org/0000-0003-0833-8850"]},"institutions":[{"id":"https://openalex.org/I4210145324","display_name":"H\u00f4pitaux Universitaires de Strasbourg","ror":"https://ror.org/04bckew43","country_code":"FR","type":"healthcare","lineage":["https://openalex.org/I4210145324"]}],"countries":["FR"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Edouard Hirsch","raw_affiliation_strings":["Neurology Clinic, University Hospital of Strasbourg, Strasbourg, France"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology Clinic, University Hospital of Strasbourg, Strasbourg, France","institution_ids":["https://openalex.org/I4210145324"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016784917","display_name":"Martin E. Johnson","orcid":"https://orcid.org/0000-0002-8398-5436","observed_orcids":["https://orcid.org/0000-0002-8398-5436"]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Martin Johnson","raw_affiliation_strings":["UCB Pharma, Raleigh, North Carolina, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Raleigh, North Carolina, U.S.A","institution_ids":["https://openalex.org/I4210127098"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5025460752","display_name":"Ursula Falter","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I85722119","display_name":"UCB Pharma (Belgium)","ror":"https://ror.org/01n029866","country_code":"BE","type":"company","lineage":["https://openalex.org/I85722119"]}],"countries":["BE"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Ursula Falter","raw_affiliation_strings":["UCB Pharma, Braine-l\u2019Alleud, Belgium"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Braine-l\u2019Alleud, Belgium","institution_ids":["https://openalex.org/I85722119"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5032020329","display_name":"Philipp von Rosenstiel","orcid":"https://orcid.org/0000-0003-1709-1271","observed_orcids":["https://orcid.org/0000-0003-1709-1271"]},"institutions":[{"id":"https://openalex.org/I4210127098","display_name":"UCB Pharma (United States)","ror":"https://ror.org/028qka468","country_code":"US","type":"company","lineage":["https://openalex.org/I4210127098","https://openalex.org/I85722119"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Philipp von Rosenstiel","raw_affiliation_strings":["UCB Pharma, Smyrna, Georgia, U.S.A"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"UCB Pharma, Smyrna, Georgia, U.S.A","institution_ids":["https://openalex.org/I4210127098"]}]}],"institutions":[],"countries_distinct_count":3,"institutions_distinct_count":4,"corresponding_author_ids":["https://openalex.org/A5059287667"],"corresponding_institution_ids":["https://openalex.org/I2800231306"],"apc_list":{"value":4360,"currency":"USD","value_usd":4360},"apc_paid":null,"fwci":5.681,"has_fulltext":true,"cited_by_count":144,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.96576923,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":100},"biblio":{"volume":"54","issue":"1","first_page":"89","last_page":"97"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12229","display_name":"Pharmacological Effects and Toxicity Studies","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2735","display_name":"Pediatrics, Perinatology and Child Health"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12267","display_name":"Diet and metabolism studies","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2737","display_name":"Physiology (medical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/brivaracetam","display_name":"brivaracetam","score":1.0},{"id":"https://openalex.org/keywords/adjunctive-antiepileptic-therapy","display_name":"adjunctive antiepileptic therapy","score":0.8930000066757202},{"id":"https://openalex.org/keywords/focal-seizures","display_name":"focal seizures","score":0.9039999842643738},{"id":"https://openalex.org/keywords/uncontrolled-epilepsy","display_name":"uncontrolled epilepsy","score":0.777999997138977},{"id":"https://openalex.org/keywords/seizure-frequency-reduction","display_name":"seizure frequency reduction","score":0.8820000290870667},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.46799999475479126},{"id":"https://openalex.org/keywords/dose-ranging-study","display_name":"dose-ranging","score":0.4390000104904175},{"id":"https://openalex.org/keywords/synaptic-vesicle-glycoprotein-2a","display_name":"SV2A","score":0.7770000100135803},{"id":"https://openalex.org/keywords/adult-epilepsy","display_name":"adults with epilepsy","score":0.7630000114440918},{"id":"https://openalex.org/keywords/antiepileptic-drug-resistance","display_name":"antiepileptic drug resistance","score":0.628000020980835},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.4830000102519989},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.4020000100135803},{"id":"https://openalex.org/keywords/dose-limiting-adverse-events","display_name":"dose-limiting adverse events","score":0.4650000035762787},{"id":"https://openalex.org/keywords/treatment-emergent-adverse-events","display_name":"treatment-emergent adverse events","score":0.4749999940395355}],"concepts":[{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8861260414123535},{"id":"https://openalex.org/C2778186239","wikidata":"https://www.wikidata.org/wiki/Q41571","display_name":"Epilepsy","level":2,"score":0.6018422245979309},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5996776819229126},{"id":"https://openalex.org/C3018162438","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Adjunctive treatment","level":2,"score":0.4949137568473816},{"id":"https://openalex.org/C3019985608","wikidata":"https://www.wikidata.org/wiki/Q7140388","display_name":"Partial epilepsy","level":3,"score":0.4888266921043396},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.4663841724395752},{"id":"https://openalex.org/C2777803345","wikidata":"https://www.wikidata.org/wiki/Q7140388","display_name":"partial seizures","level":3,"score":0.4382942020893097},{"id":"https://openalex.org/C2777010014","wikidata":"https://www.wikidata.org/wiki/Q852376","display_name":"Convulsion","level":3,"score":0.43765684962272644},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.37129539251327515},{"id":"https://openalex.org/C187212893","wikidata":"https://www.wikidata.org/wiki/Q123028","display_name":"Pediatrics","level":1,"score":0.35814368724823},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2602657079696655},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.24520060420036316},{"id":"https://openalex.org/C118552586","wikidata":"https://www.wikidata.org/wiki/Q7867","display_name":"Psychiatry","level":1,"score":0.12930375337600708}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000927","descriptor_name":"Anticonvulsants","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D002352","descriptor_name":"Carrier Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004268","descriptor_name":"DNA-Binding Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004359","descriptor_name":"Drug Therapy, Combination","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004828","descriptor_name":"Epilepsies, Partial","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011760","descriptor_name":"Pyrrolidinones","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D011760","descriptor_name":"Pyrrolidinones","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D011760","descriptor_name":"Pyrrolidinones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D014157","descriptor_name":"Transcription Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D029681","descriptor_name":"Arabidopsis Proteins","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1111/j.1528-1167.2012.03598.x","doi":"https://doi.org/10.1111/j.1528-1167.2012.03598.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1528-1167.2012.03598.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1528-1167.2012.03598.x","source":{"id":"https://openalex.org/S203153751","display_name":"Epilepsia","issn_l":"0013-9580","issn":["0013-9580","1528-1157","1528-1167"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"journal-article"},{"id":"pmid:22813235","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22813235","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"Clinical Trial, Phase II"},{"id":"pmh:oai:lirias2repo.kuleuven.be:123456789/420848","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/22813235","pdf_url":null,"source":{"id":"https://openalex.org/S4306401954","display_name":"Lirias (KU Leuven)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I99464096","host_organization_name":"KU Leuven","host_organization_lineage":["https://openalex.org/I99464096"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia, vol. 54 (1), (89-97)","raw_type":"info:eu-repo/semantics/article"}],"best_oa_location":{"id":"doi:10.1111/j.1528-1167.2012.03598.x","doi":"https://doi.org/10.1111/j.1528-1167.2012.03598.x","is_oa":true,"landing_page_url":"https://doi.org/10.1111/j.1528-1167.2012.03598.x","pdf_url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/j.1528-1167.2012.03598.x","source":{"id":"https://openalex.org/S203153751","display_name":"Epilepsia","issn_l":"0013-9580","issn":["0013-9580","1528-1157","1528-1167"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-2","ki-jl-1","medline","norway-1","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Epilepsia","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320337846","display_name":"UCB Pharma","ror":"https://ror.org/01n029866"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W1502126985.pdf","grobid_xml":"https://content.openalex.org/works/W1502126985.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W1576738253","https://openalex.org/W2004177049","https://openalex.org/W2025797846","https://openalex.org/W2037616672","https://openalex.org/W2055249621","https://openalex.org/W2061209838","https://openalex.org/W2063476303","https://openalex.org/W2066303030","https://openalex.org/W2077659055","https://openalex.org/W2095271866","https://openalex.org/W2107427879","https://openalex.org/W2117025783","https://openalex.org/W2120228951","https://openalex.org/W2126911848","https://openalex.org/W2134247911","https://openalex.org/W2582757403","https://openalex.org/W4206572492","https://openalex.org/W4239594659","https://openalex.org/W4247796277"],"related_works":["https://openalex.org/W1992028227","https://openalex.org/W1916788136","https://openalex.org/W2134247911","https://openalex.org/W1490310274","https://openalex.org/W2472978162","https://openalex.org/W2480004538","https://openalex.org/W1981401201","https://openalex.org/W2051013481","https://openalex.org/W2415570348","https://openalex.org/W6902342975"],"abstract_inverted_index":{"PURPOSE:":[0],"To":[1,56],"evaluate":[2],"the":[3,60,150,163,190,229,249,253,281,310,347,355,362,371,380,424,448],"efficacy":[4,168,450,469],"and":[5,145,181,211,239,264,300,330,358,415,439],"tolerability":[6],"of":[7,91,118,125,435],"adjunctive":[8,436],"brivaracetam":[9],"(BRV),":[10],"a":[11,74,89,111,195,420],"novel":[12],"high-affinity":[13],"synaptic":[14],"vesicle":[15],"protein":[16],"2A":[17],"ligand":[18],"that":[19],"also":[20],"displays":[21],"inhibitory":[22],"activity":[23],"at":[24],"neuronal":[25],"voltage-dependent":[26],"sodium":[27],"channels,":[28],"in":[29,51,59,88,155,224,248,354,361,370,406,423,442],"adult":[30],"epilepsy":[31],"patients":[32,52,62,127,340,352],"with":[33,80,272,289,321,366,386,444,462],"uncontrolled":[34,445],"partial-onset":[35,71,157,225,344,446],"seizures.":[36],"METHODS:":[37],"A":[38,104,123],"phase":[39,432],"IIb,":[40],"double-blind,":[41,430],"randomized,":[42],"placebo-controlled,":[43,431],"parallel-group,":[44],"dose-ranging":[45],"study":[46,434],"(N01114;":[47],"NCT00175929)":[48],"was":[49,108,199,232,257,472],"conducted":[50],"aged":[53],"16-65":[54],"years.":[55],"be":[57],"included":[58],"study,":[61],"were":[63,86,128,284,316,341,383,409,464],"required":[64],"to":[65,93],"have":[66],"experienced":[67],"four":[68],"or":[69,102],"more":[70],"seizures":[72,345],"during":[73,162,189,228,280,346,379],"4-week":[75],"prospective":[76],"baseline,":[77],"despite":[78],"treatment":[79,116,193,254,311,349,381,390],"1-2":[81],"concomitant":[82],"antiepileptic":[83],"drugs.":[84],"Patients":[85],"randomized":[87,129],"ratio":[90,294],"1:1:1":[92],"receive":[94],"BRV":[95,203,407,437,471],"50":[96],"mg/day":[97,100],"(BRV50),":[98],"150":[99,440],"(BRV150),":[101],"placebo.":[103,275],"3-week":[105],"up-titration":[106],"period":[107,114,117,166,194,231,283,350,382],"followed":[109],"by":[110],"7-week":[112,164],"maintenance":[113,165,230,282],"(total":[115],"10":[119],"weeks).":[120],"KEY":[121],"FINDINGS:":[122],"total":[124],"157":[126],"(intent-to-treat":[130],"[ITT]":[131],"population;":[132],"BRV50":[133,177,207,235,260,292,324,356],"n":[134,138,142],"=":[135,139,143,179,186,209,216,237,244,262,269,298,307,328,337],"53,":[136],"BRV150":[137,184,214,242,267,303,333,363,395],"52,":[140],"placebo":[141,161,250,287,319,372,398,425,463],"52)":[144],"overall":[146],"148":[147],"(94.3%)":[148],"completed":[149],"study.":[151],"The":[152,218,401],"percent":[153,220,277],"reduction":[154,221],"baseline-adjusted":[156],"seizure":[158,226],"frequency/week":[159,227],"over":[160],"(primary":[167],"outcome)":[169],"did":[170,452],"not":[171,453],"reach":[172,454],"statistical":[173,455],"significance":[174],"(14.7%":[175],"for":[176,183,201,206,213,234,241,259,266,274,286,291,302,318,323,332],"[p":[178,185,208,215],"0.093]":[180],"13.6%":[182],"0.124]).":[187],"However,":[188],"entire":[191],"10-week":[192,348],"statistically":[196,458],"significant":[197,459],"difference":[198],"observed":[200,465],"both":[202],"groups":[204,391,408],"(17.7%":[205],"0.026]":[210],"16.3%":[212,273],"0.043]).":[217],"median":[219],"from":[222,343],"baseline":[223],"38.2%":[233],"(p":[236,243,261,268],"0.017)":[238],"30.0%":[240],"0.113)":[245],"versus":[246],"18.9%":[247],"group.":[251,426],"During":[252,309],"period,":[255,312],"this":[256,429],"34.9%":[258],"0.004)":[263],"28.3%":[265],"0.070)":[270],"compared":[271,288,320,365,461],"Fifty":[276],"responder":[278,314],"rates":[279,315],"23.1%":[285],"39.6%":[290],"(odds":[293],"[OR]":[295],"2.17,":[296],"p":[297,306,327,336],"0.077)":[299],"33.3%":[301],"(OR":[304,325,334],"1.66,":[305],"0.261).":[308],"50%":[313],"17.3%":[317],"35.8%":[322],"2.69,":[326],"0.038)":[329],"30.8%":[331],"2.15,":[335],"0.114).":[338],"Nine":[339],"free":[342],"(five":[351],"[9.4%]":[353],"group":[357,364],"three":[359],"[5.8%]":[360],"one":[367],"patient":[368],"[1.9%]":[369],"group).":[373],"Treatment-emergent":[374],"adverse":[375],"events":[376],"(TEAEs)":[377],"reported":[378,404],"mostly":[384],"mild-to-moderate":[385],"similar":[387],"incidence":[388,422],"across":[389],"(BRV50":[392],"36/53,":[393],"67.9%;":[394],"35/52,":[396],"67.3%;":[397],"37/52,":[399],"71.2%).":[400],"most":[402],"frequently":[403],"TEAEs":[405],"headache,":[410],"fatigue,":[411],"nasopharyngitis,":[412],"nausea,":[413],"somnolence,":[414],"dizziness,":[416],"although":[417],"nausea":[418],"had":[419],"higher":[421],"SIGNIFICANCE:":[427],"In":[428],"IIb":[433],"(50":[438],"mg/day)":[441],"adults":[443],"seizures,":[447],"primary":[449],"analysis":[451],"significance;":[456],"however,":[457],"differences":[460],"on":[466],"several":[467],"secondary":[468],"outcomes.":[470],"well":[473],"tolerated.":[474]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W1502126985","counts_by_year":[{"year":2026,"cited_by_count":7},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":8},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":9},{"year":2020,"cited_by_count":10},{"year":2019,"cited_by_count":10},{"year":2018,"cited_by_count":11},{"year":2017,"cited_by_count":20},{"year":2016,"cited_by_count":22},{"year":2015,"cited_by_count":15},{"year":2014,"cited_by_count":8},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":2}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
